Filing Flows

Filing Flows › Inhibrx Biosciences (INBX) › Who owns the stock

Who owns Inhibrx Biosciences (INBX) stock

154 funds reported Inhibrx Biosciences (INBX) shares in their latest 13F filings, worth $1.4B in all. The largest holder is Morgan Stanley ($124M). Last quarter 97 funds added to their stakes and 56 cut them.

Largest holders of INBX (13F)Largest holders of INBX (13F)Morgan Stanley$124MPerceptive Advisors LLC$123MSanofi$110MViking Global Investors LP$106MHighTower Advisors, LLC$82.5MBank of America$79.7MBlackRock$78.3MSchonfeld Strategic Advisors LLC$66.1MState Street$60.7MVanguard Group$49.2M

Largest holders (13F)

FundSharesValueChangeQuarter
Morgan Stanley1,308,051$124Mincrease2026-06-30
Perceptive Advisors LLC1,297,763$123Mdecrease2026-06-30
Sanofi1,157,926$110Munchanged2026-06-30
Viking Global Investors LP1,123,929$106Mdecrease2026-06-30
HighTower Advisors, LLC870,551$82.5Mincrease2026-06-30
Bank of America841,141$79.7Mincrease2026-06-30
BlackRock825,972$78.3Mincrease2026-06-30
Schonfeld Strategic Advisors LLC697,586$66.1Mincrease2026-06-30
State Street640,458$60.7Mincrease2026-06-30
Vanguard Group623,084$49.2Mincrease2025-12-31
Vanguard Capital Management LLC492,477$46.7Mincrease2026-06-30
Woodline Partners LP400,892$38.0Mincrease2026-06-30
Capital Research Global Investors363,050$34.4Mdecrease2026-06-30
Goldman Sachs Group338,176$32.0Mincrease2026-06-30
PFM Health Sciences, LP308,385$29.2Mincrease2026-06-30

Inhibrx Biosciences' latest quarter

Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most INBX stock?

By the latest 13F filings: Morgan Stanley ($124M); Perceptive Advisors LLC ($123M); Sanofi ($110M); Viking Global Investors LP ($106M); HighTower Advisors, LLC ($82.5M).

What is the short interest in INBX?

3,417,073 shares were sold short at the 2026-10-15 settlement, -0.45% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.